Clinical Pharmacokinetics

, Volume 56, Issue 5, pp 515–523 | Cite as

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  • Kevin J. Freise
  • Aksana K. Jones
  • Doerthe Eckert
  • Sven Mensing
  • Shekman L. Wong
  • Rod A. Humerickhouse
  • Walid M. Awni
  • Ahmed Hamed Salem
Original Research Article

Abstract

Background

Venetoclax is a selective, potent, first-in-class B-cell lymphoma-2 inhibitor that restores apoptosis in cancer cells and has demonstrated efficacy in a variety of hematological malignancies.

Objective

The objective of this research was to characterize the relationship between venetoclax exposures and efficacy and safety in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Methods

A total of 272 and 338 patients from four clinical studies were pooled for the exposure–efficacy and exposure–safety analyses, respectively. Demographics, baseline disease characteristics, and select co-medications were evaluated for their impact on efficacy (lymphocytes, tumor size, objective response [OR]) and safety (neutropenia and infection).

Results

Higher venetoclax concentrations led to a more rapid decrease in lymphocyte counts and tumor size, which translated into patients more rapidly achieving OR. The 17p deletion somatic mutation was not identified, in any of the analyses, to affect the responsiveness of patients to venetoclax. Model-based simulations of lymphocyte counts and tumor size estimated an OR rate (ORR) of 84.8 % (95 % confidence interval 81.5–88.0 %) at a venetoclax dosage of 400 mg daily, with minimal increase in ORR at higher doses. The safety analyses of the adverse events (grade 3 or higher) of neutropenia and infection indicated that higher average venetoclax concentrations were not associated with an increase in adverse events.

Conclusions

The exposure–response analyses indicated that a venetoclax dosage regimen of 400 mg daily results in a high (>80 %) probability of achieving OR in R/R CLL/SLL patients, with minimal probability of increasing neutropenia or infection with higher exposures.

Supplementary material

40262_2016_453_MOESM1_ESM.pdf (968 kb)
Supplementary material 1 (PDF 968 kb)

References

  1. 1.
    Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.CrossRefPubMedGoogle Scholar
  2. 2.
    AbbVie. Venclexta (venetoclax) tablets full prescribing information. North Chicago: AbbVie; 2016.Google Scholar
  3. 3.
    Willis S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. J Cell Sci. 2003;116(Pt 20):4053–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature. 2002;415(6874):922–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39(11):615–47.CrossRefPubMedGoogle Scholar
  6. 6.
    Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590–607.CrossRefPubMedGoogle Scholar
  7. 7.
    Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Gerecitano JF, Roberts AW, Seymour JF, Wierda WG, Kahl BS, Pagel JM, et al. A phase 1 study of venetoclax (ABT-199 / GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;126(23):254.Google Scholar
  9. 9.
    Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results. Blood. 2015;126(23):3038.Google Scholar
  10. 10.
    DiNardo C, Pollyea D, Pratz K, Thirman MJ, Letai A, Frattini M, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood. 2015;126(23):327.Google Scholar
  11. 11.
    Ma S, Brander DM, Seymour JF, Kipps TJ, Barrientos JC, Davids MS, et al. Deep and durable responses following venetoclax (ABT-199 / GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. Blood. 2015;126(23):494.Google Scholar
  12. 12.
    Stilgenbauer S, Eichhorst Barbara, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.CrossRefPubMedGoogle Scholar
  13. 13.
    Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. doi:10.1158/2159-8290.cd-16-0313. (Epub 12 Aug 2016).
  14. 14.
    Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7(279):279ra40.CrossRefPubMedGoogle Scholar
  15. 15.
    Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K, et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol Res Perspect. 2015;3(5):e00178.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Jaglowski S, Jones JA. Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011;11(9):1379–90.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Francis S, Karanth M, Pratt G, Starczynski J, Hooper L, Fegan C, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107(5):1023–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Geisler CH, Philip P, Christensen BE, Hou-Jensen K, Pedersen NT, Jensen OM, et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res. 1997;21(11–12):1011–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2010;2010:481–8.Google Scholar
  21. 21.
    Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24(3):437–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Jones AK, Freise KJ, Agarwal S, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics, a selective BCL-2 inhibitor, in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016;18(5):1192–202.CrossRefPubMedGoogle Scholar
  23. 23.
    Jones AK, Freise KJ, Agarwal S, Verdugo M, Humerickhouse RA, Wong SL, Salem AH. Venetoclax pharmacokinetics in hematological malignancies subjects with renal and hepatic impairment. American College of Clinical Pharmacology Annual Meeting. 2016. September 25–27, North Bethesda, MD.Google Scholar
  24. 24.
    Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a Bcl-2 Inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. doi:10.1002/jcph.730. (Epub 7 Mar 2016).
  25. 25.
    Salem AH, Agarwal S, Dunbar M, Nuthalapati S, Chien D, Freise KJ, et al. Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective first-in-class Bcl-2 inhibitor. J Clin Pharmacol. doi:10.1002/jcph.741. (Epub 31 Mar 2016).
  26. 26.
    Salem AH, Agarwal SK, Dunbar M, Enschede SLH, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin’s lymphoma. J Clin Pharmacol. doi:10.1002/jcph.821. (Epub 25 Aug 2016).
  27. 27.
    Jones J, Mato AR, Coutre S, Wierda W, Choi MY, Davids MS, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. Blood. 2015;126(23):715.Google Scholar
  28. 28.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.CrossRefPubMedGoogle Scholar
  30. 30.
    Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002;4(4):E27.CrossRefPubMedGoogle Scholar
  31. 31.
    van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JA, Vrisekoop N, et al. In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res. 2008;68(24):10137–44.CrossRefPubMedGoogle Scholar
  32. 32.
    Committee for Medicinal Products for Human Use (CHMP). Guideline on evaluation of anticancer medicinal products in man. London: European Medicines Agency (EMA); 2016.Google Scholar
  33. 33.
    Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302–6.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013;54(8):1823–5.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, et al. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood. 2016;127(25):3192–201.CrossRefPubMedGoogle Scholar
  36. 36.
    Chiron D, Dousset C, Brosseau C, Touzeau C, Maiga S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6(11):8750–9.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014;123(26):4132–5.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol. 2014;32(27):3039–47.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Kevin J. Freise
    • 1
  • Aksana K. Jones
    • 1
  • Doerthe Eckert
    • 1
  • Sven Mensing
    • 1
  • Shekman L. Wong
    • 1
  • Rod A. Humerickhouse
    • 1
  • Walid M. Awni
    • 1
  • Ahmed Hamed Salem
    • 1
  1. 1.Abbvie Inc.North ChicagoUSA

Personalised recommendations